A quest for staunch effects of flavonoids: Utopian protection against hepatic ailments  by Dhiman, Anju et al.
Arabian Journal of Chemistry (2016) 9, S1813–S1823King Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comREVIEWA quest for staunch eﬀects of ﬂavonoids: Utopian
protection against hepatic ailments* Corresponding author. Address: Department of Pharmaceutical
Sciences, Maharshi Dayanand University, Rohtak, India. Tel.: +91
1262 393232; mobile: +91 9896436152.
E-mail address: ad_mdu@rediffmail.com (A. Dhiman).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.arabjc.2012.05.001
1878-5352 ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Anju Dhiman a,*, Arun Nanda a, Sayeed Ahmad ba Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
b Bioactive Natural Product Laboratory, Department of Pharmacognosy & Phytochemistry, Faculty of Pharmacy, Jamia
Hamdard, New Delhi 110062, IndiaReceived 2 September 2011; accepted 15 May 2012
Available online 23 May 2012KEYWORDS
Antioxidant;
Flavonoids;
Hepatoprotection;
Phenolic compoundsAbstract The role of ﬂavonoids as the major red, blue and purple pigments in plants has gained
these secondary products a great deal of attention over the years. Flavonoids are polyphenols
and occur as aglycones, glycosides and methylated derivatives. Flavonoids are the main compo-
nents of a healthy diet containing fruits and vegetables and are concentrated especially in tea, apples
and onions. Till date, more than 6000 ﬂavonoids have been discovered, out of which 500 are found
in free state. They are abundant in polygonaceae, rutaceae, leguminosae, umbelliferae and compos-
itae. Flavonoids are powerful antioxidants. In addition to their role in nutrition, ﬂavonoids possess
many types of pharmacological activities, including anti-inﬂammatory, antioxidative, hepatoprotec-
tive, vasorelaxant, antiviral and anticarcinogenic effects. The present review is focused on ﬂavo-
noids derived from natural products that have shown a wise way to get a true and potentially
rich source of drug candidates against liver ailments. The present review initially highlights the cur-
rent status of ﬂavonoids and their pharmaceutical signiﬁcance, role of ﬂavonoids in hepatoprotec-
tion, therapeutic options available in herbal medicines and in later section, summarizes ﬂavonoids
as lead molecules, which have shown signiﬁcant hepatoprotective activities.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The ﬂavonoids are a diverse group of polyphenolic compounds
widely distributed in the plant kingdom (Harborne and Wil-
liams, 2000). Flavonoids are nearly ubiquitous in plants and
are recognized as the pigments responsible for the colors of
leaves, especially in autumn (Saraf et al., 2007). Flavonoids
contribute to the ﬂavor and pigmentation of the fruits and veg-
etables in the human diet (Timberlake and Henry, 1986). More
than 6000 plant ﬂavonoids have been described, and they have
been classiﬁed into at least 10 chemical groups according toO+
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Figure 1 Basic structure of various ﬂtheir structural patterns. However, laboratory and epidemiol-
ogic studies have focused on six ﬂavonoid subgroups: ﬂavones,
ﬂavonols, ﬂavan-3-ols (catechins), procyanidins, ﬂavanones,
and isoﬂavones (Theodoratou et al., 2007). They also have
important roles in plant growth, reproduction, and pathogen
and predator resistance (Harborne and Williams, 2000). These
are formed in plants and participate in the light-dependent
phase of photosynthesis during which they catalyze electron
transport (Middleton et al., 2000).
Flavonoids are present in plants either as aglycones or as gly-
coside conjugates. Attached sugar moieties include D-glucose,1'
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Figure 2 The major branch pathways of ﬂavonoid biosynthesis.
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(Ross and Kasum, 2002). The basic structure of various ﬂavo-
noids and their related compounds are given in Fig. 1. They
are prominent components of citrus fruits (Kefford and Chan-
dler, 1970) and other food sources (Herrmann, 1976) and are
consumed regularly with the human diet. It is generally recog-
nized that an increased consumption of vegetables and fruitsprotects against cancer and cardiovascular diseases (Hollman,
2004). In addition to their role in nutrition, ﬂavonoids possess
many types of pharmacological activities, including anti-inﬂam-
matory, antioxidative, hepatoprotective, antiviral and anticar-
cinogenic effects (Chen et al., 2007). This class of compounds
has become increasingly popular in terms of health protection
because they possess a remarkable spectrum of biochemical
S1816 A. Dhiman et al.and pharmacologic activities (Watjen et al., 2005). Perhaps the
most active area of ﬂavonoid research at the present time is the
possible medicinal contribution that ﬂavonoids make to human
health (Stipcevic et al., 2006). The present review is focused to
cover the current status of ﬂavonoids and their pharmaceutical
signiﬁcance, role of ﬂavonoids in hepatoprotection, therapeutic
options available in herbal medicines containing ﬂavonoids and
phenolic compounds and chemically deﬁned ﬂavonoid mole-
cules reported for hepatoprotection.
2. Biochemical pathway for ﬂavonoid biosynthesis
Flavonoids constitute a relatively diverse family of aromatic
molecules that are derived from phenyl and malonyl-coenzyme
A, CoA; via the fatty acid pathway (Shirley, 2001).
In the early steps of ﬂavonoid biosynthesis elucidated by
Woo et al. (2005) with slight modiﬁcations, in Fig. 2, phenyl-
alanine derived from the shikimic acid pathway is converted
to coumaroyl-CoA by phenylalanine ammonia-lyase, cinna-
mate 4-hydroxylase, and 4-coumarate: CoA ligase. Chalcone
synthase, the ﬁrst committed enzyme for ﬂavonoid synthesis,
results in the condensation of coumaroyl-CoA with three mol-
ecules of malonyl-CoA from acetyl-CoA to form naringenin.
Naringenin chalcone then is converted to naringenin by chal-
cone isomerase. Naringenin is further converted by glycosyla-
tion, acylation, and methylation of its three rings. The end
result of all these enzymatic steps is the synthesis of substituted
ﬂavones, ﬂavonols, catechins, deoxyﬂavonoids, and anthocya-
nins. Isoﬂavonoids are formed from naringenin or deoxyﬂavo-
noids by an aryl migration of the B-ring to the 3-position,
followed by hydroxylation at the 2-position, which is catalyzed
by isoﬂavone synthase (IFS), a cytochrome P450 enzyme. The
2-hydroxyisoﬂavone intermediate is unstable and is dehy-
drated to yield isoﬂavone (Woo et al., 2005).
Enzyme names are abbreviated as: cinnamate-4-hydroxylase
(C4H), chalcone isomerase (CHI), chalcone synthase (CHS),
7,29-dihydroxy, 49-methoxyisoﬂavanol dehydratase (DMID),
ﬂavanone 3-hydroxylase (F3H), ﬂavone synthase (FSI and
FSII), isoﬂavone O-methyltransferase (IOMT), isoﬂavone
reductase (IFR), isoﬂavone synthase (IFS), leucoanthocyanidin
dioxygenase (LDOX), leucoanthocyanidin reductase (LCR),
O-methyltransferase (OMT), phe ammonia-lyase (PAL),
rhamnosyl transferase (RT), stilbene synthase (STS), UDPG
ﬂavonoid glucosyl transferase (UFGT) and vestitone reductase
(VR).3. Flavonoids in pharmaceuticals
Epidemiological studies have shown that a diet rich in plant-
derived food is consistently associated with a reduced risk of
developing chronic diseases. Flavonoids are also common con-
stituents of plants used in traditional medicine to treat a wide
range of diseases (Lazaro, 2009). Flavonoids are postulated to
play pivotal roles in the adaptation to their biological environ-
ments both as defensive compounds (phytoalexins) and as
chemical signals (Li and Jiang, 2007). Quercetin, the most
abundant ﬂavonoid in nature, present in large amounts in veg-
etable, fruits, tea, and olive oil, and because it contains a num-
ber of phenolic hydroxyl groups, it exhibits its therapeutic
potential against many diseases, including ischemic heart
diseases, atherosclerosis, liver ﬁbrosis, renal injury, andchronically biliary obstruction (Mandal et al., 2007). Green
tea, especially its major polyphenolic constituent, epigallocate-
chin-3-gallate, has received much attention as a potential can-
cer chemopreventive agent (Phosrithong and Ungwitayatorn,
2009). Medicinally important ﬂavonoids, along with their
pharmaceutical signiﬁcance are discussed as follows:
3.1. Flavonoids as anticancer agents
Flavonoid and its derivatives possessing p-glycoprotein inhib-
itory effects may become candidates of effective agents in can-
cer chemotherapy. The important mechanism by which
ﬂavonoids exert their in vivo chemoprotective effects is through
their inhibition of efﬂux transporters and metabolizing en-
zymes, such as CYP i.e., cytochrome P-450 (Bansal et al.,
2009). Detailed studies have revealed that quercetin exerted a
dose-dependent inhibition of growth and colony formation.
The ﬂavonoids like kaempferol, catechin, toxifolin and ﬁsetin
are also reported to suppress cell growth (Tapas et al., 2008).
3.2. Flavonoids as antibacterial agents
Flavonoids like rutin, naringin and baicalin possess antibacte-
rial activity (Sharma, 2006). Flavonoids are hydroxylated phe-
nolic substances but occur as a C6–C3 unit linked to an
aromatic ring (Cowan, 1999). Since they are known to be syn-
thesized by plants in response to microbial infection, it should
not be surprising that they have been found in vitro to be effec-
tive antimicrobial substances against a wide array of microor-
ganisms. Their activity is probably due to their ability to
complex with extracellular and soluble proteins and to com-
plex with bacterial cell walls, as in case of quinones. More lipo-
philic ﬂavonoids may also disrupt microbial membranes (Firas
and Hassan, 2008). Flavonoid compounds also exhibit inhibi-
tory effects against multiple viruses. Numerous studies have
documented the effectiveness of ﬂavonoids such as swertifran-
cheside, glycyrrhizin and chrysin against human immunodeﬁ-
ciency virus (HIV) (Cowan, 1999).
3.3. Flavonoids as antiprotozoans
Flavonoids, especially those isolated from plants, have been
demonstrating promising antileishmanial and antitrypanoso-
mal activities. Baccharis species have been the source of antile-
ishmanial and antimalarial compounds, with active phenolics
and triterpenoids. The methanolic extracts of B. trimera have
also been shown to be effective against cutaneous species of
leishmania, including signiﬁcant activity against pathogenic
yeasts (Grecco et al., 2010). The antioxidant, antiprotozoal
and suppressive effects of ﬂavonoids on CYP enzymes and
p-glycoproteins indicate that they can be synergistically
combined with currently used antiparasitic drugs, instead of
in substitution to those drugs, to extend their life span, to in-
crease their bioavailability and to delay the development of
drug resistance by parasites and microorganisms (Ferreira
and Luthria, 2010).
3.4. Flavonoids as anti ulcer and gastroprotective agents
Peptic ulcer is a chronic and appalling disease. Today, it is dom-
inant among the diseases that affect the world’s population. The
A quest for staunch effects of ﬂavonoids: Utopian protection S1817principal factors causing this disease are inadequate dietetic
habits, prolonged use of non-steroidal anti-inﬂammatory drugs,
stress and infection by Helicobacter pylori, in addition to other
factors of genetic origin (Falcao et al., 2008). Several mecha-
nisms have been proposed to explain the gastroprotective effect
of ﬂavonoids; these include increase of mucosal prostaglandin
content, decrease of histamine secretion frommast cells by inhi-
bition of histidine decarboxylase and inhibition of H. pylori
growth (Borrelli and Izzo, 2000).Most of these effects have been
attributed to the inﬂuence of ﬂavonoids on arachidonic acid
metabolism, their vasoprotective action and their ability to
interfere with the formation of histamine in the gastric mucosa
(Nwafor, 2004).3.5. Flavonoids as hepatoprotective
Flavonoids represent a beneﬁcial group of naturally occurring
compounds with hepatoprotective potentials. Hepatoprotec-
tive potential of some ﬂavonoids may be owing to their antiox-
idant activity and capability of normalization of impaired
membrane function activity (Mukherjee et al., 2009). Silymarin
is a natural extract with hepatoprotective properties composed
mainly of ﬂavonolignans, with silibinin being its principal con-
stituent (Khabiya and Joshi, 2010). The aqueous extract of
Psidium guajava Linn. leaves showed good hepatoprotective
activity in carbon tetrachloride induced acute and chronic liver
damage, paracetamol induced liver damage and thioacetamide
induced liver necrosis (Roy et al., 2006). The ﬂavonoid rich
alcoholic extract of Thuja occidentalis was found to possess
good hepatoprotective property against carbon tetrachloride
induced liver damage (Dubey and Batra, 2008).
3.6. Flavonoids on cardiovascular system: vasorelaxing effect
To date, a substantial number of studies have reported the efﬁ-
cacy of dietary ﬂavonoids or plant foods or extracts in reduc-
ing biomarkers of cardiovascular disease risk in acute and
short-term interventions with healthy volunteers and at-risk
population groups (Hooper et al., 2008). Flavonoids have
strong antioxidant properties in vitro, and investigators
hypothesized that reduced cardiovascular risk might reﬂect
an antioxidant effect, including an ability to scavenge reactive
oxygen species and prevent oxidative modiﬁcation of low den-
sity lipoprotein, a critical step in atherogenesis (Shenouda and
Vita, 2007). Animal studies as well as human studies, although
limited in number, have shown beneﬁcial changes in biological
phenomena related to cardiovascular health after the con-
sumption of polyphenol rich foods such as cocoa, red wine,
and tea (Erlund et al., 2008).
3.7. Flavonoids as neuroprotective agents
Synthetic ﬂavonoids, such as 6-bromoﬂavone and 6-bromo-30-
nitroﬂavones, were shown to displace [3H] ﬂumazenil binding
to membranes from rat cerebellum but not from spinal cord,
indicating selectivity for the BZ-Omega receptor subtype, but
the latter was more potent than 6-bromoﬂavone. Results from
tail conﬂict tests in rats showed that these synthetic ﬂavonoids
possess anxiolytic like properties similar or superior to that of
diazepam (Tapas et al., 2008).3.8. Flavonoids as anti-inﬂammatory
Plant ﬂavonoids show anti-inﬂammatory activity in vitro and
in vivo (Kim et al., 2004). Effects of ﬂavonoids on a variety
of inﬂammatory processes have been object of diverse reviews
and it has been demonstrated that they are able to inhibit a ser-
ies of enzymes which are activated in the course of the inﬂam-
matory process. Prostaglandins and nitric oxide biosynthesis is
involved in inﬂammation, and isoforms of inducible nitric
oxide synthase (iNOS) and of cyclooxygenase (COX-2) are
responsible for the production of a great amount of these
mediators. In vitro studies have conﬁrmed that the ﬂavonoid
quercetin inhibits nitric oxide production and the expression
of iNOS. Although the inhibition of iNOS can contribute to
the anti-inﬂammatory effect of ﬂavonoids, the mechanism
responsible for such effect is not known in depth (Gallego
et al., 2007).
3.9. Flavonoids as anti-diabetic agents
So far, many anti-diabetic ﬂavonoids have been reported, such
as myricetin with insulinomimetic effects, quercetin with
anti-diabetic effects in streptozotocin induced diabetic rats, and
kaempferol-3,7-O-(a) dirhamnoside with hypoglycemic and
antioxidant effects (Zhu et al., 2010). Some ﬂavonoids and poly-
phenols, as well as sugar derivatives, are found to be effective
against the inhibitory activities of a-glucosidase and aldose
reductase or other treatment approaches to diabetes (Jung
et al., 2006). Long term effects of diabetes include progressive
development of speciﬁc complements such as retinopathy,
which affects eyes and lead to blindness; nephropathy in which
the renal functions are altered or disturbed and neuropathy
which is associated with the risks of amputations, foot ulcers
and features of autonomic disturbance including sexual dys-
functions. Numerous studies report the anti-diabetic effects of
polyphenols. Tea catechins have been investigated for their
anti-diabetic potential (Pandey and Rizvi, 2009). Hesperetin
has the potential to treat multiple ocular diseases like diabetic
retinopathy, diabetic macular edema and cataract, by virtue
of its wide-ranging pharmacological activities (Srirangam and
Majumdar, 2010). Trigonella foenum graecum seeds are also
known to possess a hypolipidemic effect and also offer antilith-
ogenic potential due to its encouraging effect on cholesterol
metabolism. Its seed has also been shown to be effective in the
prevention of retinopathy and other diabetic complications
when used alone or in combination with sodium orthovandate
(Pandey and Rizvi, 2009).
3.10. Flavonoids as antioxidants
The best described property of phenolics is the antioxidant
capability toward free radicals normally produced by cells
metabolism or in response to external factors (Leopolsdini
et al., 2011). Flavonoids, a group of naturally occurring benzo
c-pyrone derivatives, have been shown to possess several bio-
logical properties (including hepatoprotective, anti-thrambotic,
anti-inﬂammatory, and antiviral activities), many of which may
be related, partially at least, to their antioxidant and free-radi-
cal-scavenging ability (Theodoratou et al., 2007; Middleton
et al., 2000). Antioxidants are radical scavengers, which protect
the human body against free radicals (Qureshi et al., 2010).
S1818 A. Dhiman et al.These are the compounds, that protect cells against the damag-
ing effects of reactive oxygen species, such as singlet oxygen,
superoxide, peroxyl radicals, hydroxyl radicals and peroxyni-
trite. An imbalance between antioxidants and reactive oxygen
species results in oxidative stress, leading to cellular damage.
Oxidative stress has been linked to cancer, aging, atherosclero-
sis, ischemic injury, inﬂammation and neurodegenerative dis-
eases (Parkinson’s and Alzheimer’s). Many ﬂavonoids may
help to provide protection against these diseases by contribut-
ing, along with antioxidant vitamins and enzymes, to the total
antioxidant defense system of the human body. Epidemiologi-
cal studies have shown that ﬂavonoid intake is inversely related
to mortality from coronary heart disease and to the incidence of
heart attacks. A variety of ﬂavonoids control the oxidation at
the cellular level as antioxidants by interfering with enzyme
activity, chelating of redox-active metals and by scavenging free
radicals (Saraf et al., 2007).
4. Role of ﬂavonoids in hepatoprotection
Chronic liver diseases represent a major health burden world-
wide, with liver cirrhosis being the ninth leading cause of death
in Western countries (Kim et al., 2002). Many ayurvedic med-
icines are used for treating liver disorders. Thus search for
crude drugs of plant origin with antioxidant activity has be-
come a central focus of study of hepatoprotection (Usha
et al., 2007). The antiradical property of ﬂavonoids is directed
mostly toward HO; and O2 as well as peroxyl and alkoxyl rad-
icals (Saija et al., 1995). Because of the high reactivity of the
hydroxyl group of the ﬂavonoids, radicals are made inactive,
according to the following equation:
FlavonoidðOHÞ þR ! FlavonoidðOÞ þRH ð1Þ
where R is a free radical and O is an oxygen free radical. Se-
lected ﬂavonoids can directly scavenge superoxides, whereas
other ﬂavonoids can scavenge the highly reactive oxygen de-
rived radical called peroxynitrite (Nijveld et al., 2001). Due
to their low redox potentials (0.23 < E7 < 0.75 V), ﬂavonoids
(Fl–OH) are thermodynamically able to reduce highly oxidiz-
ing free radicals with redox potentials in the range 2.13–
1.0 V, by hydrogen atom donation:
FlOHþR ! FlO þRH ð2Þ
where R represents superoxide anion, peroxyl, alkoxyl, and
hydroxyl radicals.
The aroxyl radical (Fl–O) may react with a second radical,
acquiring a stable quinine structure. (Meng et al., 2010).
In natural conditions, most of the ﬂavonoids occur as gluco-
sides bound to the sugar moiety and are highly stable and water
soluble (Srivastava and Gupta, 2009). Many of the ﬂavonoids
are widely described as antioxidants and have many types of
pharmacological actions (Cheng and Breen, 2000). Diverse
medical applications for tea ﬂavonoids e.g., as chemiprotectors
against cancer and cardiovascular disease, hepatoprotectors
and antioxidants are reported (Alvarez et al., 2008). Among
the many hepatoprotective herbs/compounds, milk thistle
(Silybum marianum), glycyrrhizin, Bupleurum chinense (Saiko),
Schisandra chinensis (Wuweizi) and Phyllanthus amarus used
in traditional Chinese medicine have been most extensively
studied and documented (Wang et al., 2007a). Silybum extracts
are being used from centuries for the treatment of liver diseases
(hepatitis, cyrosis, and icterus), against the intoxication withAmanita species, and also in the case of peoples with alcoholic
problems. The hepatoprotective effect of these extracts (against
hepatotoxicity of carbon tetrachloride, paracetamole, or
Dgalactosamine) are due to the antioxidant properties of ﬂavo-
noids, to the inhibition of the synthesis of phosphatidylcholine,
and stimulating of hepatic synthesis of RNA proteins; silybin
also stimulate the RNApolymerase I, and further the ribosomal
RNA and the protein synthesis (Hadaruga and Hadaruga,
2009). A variety of substances which might contribute to hepa-
toprotective activity have also been identiﬁed in extracts of
Anogeissus latifolia including tannins, gallic acid, ellagic acid
and ﬂavonoids such as lutin and quercetin, which are potential
antioxidants (Pradeep, 2009).
Naringin is reported to inhibit nitrite induced methhemo-
globin formation by scavenging superoxide, hydroxyl & other
radicals (Kumar et al., 2003). Naringin exhibited antioxidant
capacity based on increasing the gene expression of superoxide
dismutase and catalase activities, & glutathione peroxidase and
thereby increasing the hepatic superoxide dismutase and cata-
lase activities, protecting the plasme vitamin E, and decreasing
the hepatic mitochondrial H2O2 content (Jeon et al., 2001).
Naringin is also shown to have hepatoprotective action (Choe
et al., 2001).
Phenolic compounds acting as antioxidants may function
as terminators of free radical chains and as chelators of
redox-active metal ions that are capable of catalyzing lipid
peroxidation (Flora, 2009). The ﬂavonoids, such as apigenin-
7-glucoside, luteolin-7-glucoside and quercitin prevented the
glutathione depletion and lipid peroxidation induced by an
acute intoxication with carbon tetrachloride, ethanol, acetomi-
nophen and bromobenzene in the liver and in the rats with bil-
iary obstruction (Babenko and Shakhova, 2008). Genistein is
an isoﬂavone found primarily in the soy protein. Administra-
tion of oral genistein was established to reduce lipid peroxida-
tion in the liver and to increase total antioxidant capacity in
hamsters (Kuzu, 2007).
The ﬂavonoids are typical phenolic compounds that act as
potent metal chelators and free radical scavengers, and which
modulate intracellular signaling caused by upstream binding
partners, such as, regulatory kinases and receptors (Min,
2009). The capacity of ﬂavonoids to act as antioxidants de-
pends upon their molecular structure ((Wang et al., 2007b).
Characteristics of ﬂavonoid structure for most effective radi-
cal-scavenging activity are:
1. The catechol (o-dihydroxy) group in the ring confers great
scavenging ability.
2. A pyrogallol (trihydroxy) group in ring B of a catechol, as
in myricetin, produces even higher activity. The C2–C3
double bond of the C-ring appears to increase scavenger
activity because it confers stability to the phenoxy radical
produced.
3. The 4-oxo (keto double bond at position 4 of the C-ring),
especially in association with the C2–C3 double bond,
increases scavenger activity by delocalizing electrons from
B-ring.
4. The 3-OH group on the C-ring generates an extremely
active scavenger; in fact, the combination of C2–C3 double
bond and 4-oxo group appears to be the best combination
on the top of the catechol group.
5. The 5-OH and 7-OH groups may also add scavenging
potential in certain cases (Tapas et al., 2008).
Table 1 List of medicinal plants used as hepatoprotective in Ayurveda (Sharma et al., 1993).
S. No. Scientiﬁc name (parts used) Family Common name Chemical constituents Use in TSM
1. Acorus calamus (rhizome) Araceae Vashambu Volatile oil, sesquiterpenes, asarone, acorone Nervine tonic, anti-spasmodic, wound healing,
skin diseases, bonefracture
2. Aegel marmelos Corr.(leaves) Rutaceae Vilvam Marmelosin, coumarin, umbelliferone Febrifuge, anti-diabetic, catarrh
3. Allium sativum Linn.(bulb) Liliaceae Lasan Allicin, allisatin I&II, essential oil Indigestion, skin diseases, earache. Bulb fried
with mushroom act as antidote on snake bite,
antiviral activity, inhibit cellular proliferation
of virally infected cells
4. Aloe barbadensis Mill.(plant) Ranunculaceae Gheekunvar Aloin, isobarneloin, emodin, phenolic compounds Seborrheic dermatitis, psoriasis vulgaris,
genital herpes, skin burns, diabetes (type II),
HIV infection, anticancer, ulcerative colitis
wound healing, mucositis, radiation dermatitis,
acne vulgaris, frostbite, stomatitis, constipation
5. Artemesia cappillaris (plant) Asteraceae Sweet worm wood Coumarins, ﬂavonol glycosides, aglycones Liver ailments
6. Azadirachta indica A. Juss (plant) Meliaceae Vembu Flavones, lactones Liver tonic, fever, skin diseases
7. Anethum graveolens (fruit) Umbelliferae Dilla, Shubit Flavonoids, coumarins, phenolic acids Gastralgia, colic pain
8. Bergenia ligulata (root & leaves) Saxifragaceae Pasanabheda Berganine, ﬂavonols, catechins Antiviral edema, anti-inﬂammatory
9. Curcuma longa (rhizome) Zingiberaceae Haridra Curcumin Antiinﬂammatory
10. Cheiranthus cheiri Cruciferae Tudri Flavonoids, cardiac glycosides, alkaloids Anti-spasmodic, purgative
11. Carthamus tinctorius Linn (ﬂower) Compositae Saﬄower Carthamin Cardiac and cerebral vascular diseases, high
blood pressure, diabetes
12. Colchicum luteum (corms) Liliaceae Suranjan Colchicin Rheumatoid arthritis, analgesic, anti-inﬂammatory
13. Capparis spinosa (root) Capparaceae Himsra, Capers Glucocapparin ﬂavonoids, sterols, terpenes Hepatic stimulant
14. Citullus lanatus (root, seeds) Cucurbitaceae Matira Triterpenoid glucoside Demulcent, diuretic, pectoral, tonic
15. Corylus avellana (fruit) Betulaceae Hazel Flavonoids, spermidine Diuretic, astringent, diaphoretic, febrifuge, nutritive
16. Cyphomandra betacea (plant) Solanaceae Manipuri Flavonoids, lycopene Skin, diabetic patients, acidosis, eye diseases, obesity,
liver, diarrhea
17. Glycyrrhiza glabra (root) Leguminosae Yashti-madhu Glycyrrhizin, glycyrrhetic acid,
ﬂavonoids, ﬂavanones, chalcones, isoﬂavones
Laxative, antioxidant, cancer protecting,
stimulates
interferon production
18. Heydichium spicatum (rhizome) Zingiberaceae Sutti Diterpenes Vasodilatory, hypotensive, anti-spasmodic, tonic,
carminative, stimulant
19. Lithospermum oﬃcinale (plant) Boraginaceae Gomwell Naphthoquinones Antipyretic, anti gout, kidney stones, diarrhea
20. Myrtus communis (fruit) Myrtaceae Myrtle Volatile oil Hair growth, respiratory disorders
21. Nelumbo mucifera (ﬂowers) Nymphaceae Kamala Nelumbin, nupharine Astringent
22. Ocimum tenuiﬂorum (seeds, leaves) Labiatae Nagathein Volatile oil Expectorant, catarrh, bronchitis, gastric disorders,
carminative, refrigerant, febrifuge
23. Picrorhiza kurroa (rhizome) Scrophulariaceae Kutki Acetophenones, androsin, iridoid,
acetosyringenin
Jaundice, dyspepsia
24. Phyllanthus niruri Linn (plant) Euphorbiaceae Jar amla, Jangali amla Flavonoids like quercetin, rutin,
isoquercetin, astralgin, phyllanthin,
hypophyllathin
Hepatitis, jaundice, antiviral, gonorrhea, diabetes
25. Pinus roxburghii (volatile oil) Pinaceae Chir pine Beta-carotene, a & b pinene Diuretic
26. Pistacia vera (seed) Anacardiaceae Pistachio Polyphenols Antimicrobial
27. Rheum emodi Wall (rhizome) Polygonaceae Rewandchini Rhaponticin, emodin, chrysophanic acid Astringent, laxative, antibacterial
28. Pterocarpus marsupium (wood) Leguminosae Uthiravenkai Pigments Stomachache
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reported for hepatoprotection
Since the ﬂavonoids are well tolerated, widely studied and least
toxic (Vijayaraghavan et al., 2008), estimated dietary ﬂavonoid
intake can reach 50–800 mg per day, or higher, if dietary sup-
plements are consumed (Tsuji and Walle, 2008). Among the
herbal drugs, silymarin has been used as a dietary supplement
for hepatoprotection for over 2000 years (Eminzade et al.,
2008). Hesperidin is a ﬂavanone glycoside abundantly found
in sweet orange and lemon and is an inexpensive by-product
of citrus cultivation (Tirkey et al., 2005). Hesperidin ﬂavano-
glycone protects against gamma-irradiation induced hepato-
cellular damage and oxidative stress in Sprague–Dawley rats
(Kannampalli et al., 2008). Some of the polymethoxylated cit-
rus ﬂavonoids have also in preliminary studies demonstrated
antiproliferative properties (Walle, 2007). Chinese green tea
(Camellia sinensis) contains high levels of antioxidant polyphe-
nols, including catechin, epicatechin, gallocatechin, epigalloca-
techin, epicatechin gallate and gallocatechin gallate (Lehnert
et al., 2010). Examples of some medicinal plants used as hepa-
toprotective in ayurveda along with their active principles are
enlisted in Table 1.
As seen from Table 1 above, ﬂavonoids and phenolic com-
pounds are the metabolites being rapidly found in medicinal
plants, basically used for hepatoprotection. Also, in vitro
experimental systems also showed that ﬂavonoids possess
anti-inﬂammatory, antiallergic, antiviral, and anticarcinogenic
properties (Nijveld et al., 2001). So, a chemically deﬁned com-
ponent (i.e., a ﬂavonoid) of a herbal product, that can serve as
hepatotropic drug may be explored to get a true and poten-
tially rich source of drug candidates against liver ailments.
6. Important ﬂavonoids reported for hepatoprotection
The main dietary groups of ﬂavonoids are ﬂavonols (e.g.,
kaempferol, quercetin), which are found in onions, leeks, broc-
coli, ﬂavones (e.g., apigenin, luteolin), which are found in pars-
ley and celery, isoﬂavones (e.g., daidzein, genistein), which are
mainly found in soy and soy products, ﬂavanones (e.g., hes-
peretin, naringenin), which are mainly found in citrus fruit
and tomatoes, ﬂavanols (e.g., catechin, epicatechin, epigalloca-
techin, epigallocatechin gallate), which are abundant in green
tea, red wine, chocolate, and anthocyanidins (e.g., pelargoni-
din, cyanidin, malvidin), whose sources include red wine and
berry fruits (Spencer, 2007).
A large number of ﬂavonoids and phenolic compounds
have been isolated from crude plant extracts with proven hepa-
toprotective potential. Some chemically deﬁned organic mole-
cules containing ﬂavonoids and phenolic compounds as major
class/category along with their botanical source and part of the
plant which is being used in therapeutics, for hepatoprotective
potential (Adewusi and Afolayan, 2010) are listed in Table 2.
7. Conclusion
The need for new and useful compounds to provide assistance
and relief in all aspects of the human condition is ever growing.
In developing countries the availability of modern medicines is
limited. So traditional medicine is still the mainstay of health
Table 2 List of some chemically deﬁned organic molecules containing ﬂavonoids having hepatoprotective potential.
S. No. Chemical substance Plant Plant part Category References
1. Anastatin A Anastatica hierochuntica L Whole plant Flavonoids Yoshikawa et al. (2003)
2. Anastatin B Anastatica hierochuntica L Whole plant Flavonoid Yoshikawa et al. (2003)
3. 5,7,40-Trihydroxy-30-
methoxyisoﬂavone
Erycibe expansa Wall Stem Isoﬂavone Matsuda et al. (2004)
4. Genistein Erycibe expansa Wall. Stem Isoﬂavone McCarty et al. (2009)
5. Rubiadin Rubia cordifolia Linn Roots Dihydroxy
anthraquinone
Rao et al. (2006)
6. Mangiferin Salacia reticulata Roots Phenolic compound Chakraborty and
Chakraborty (2010)
7. ()-40-O-Methylepigallocatechin Salacia reticulata Roots Phenolic compound Yoshikawa et al. (2002)
8. Onitin Equisetum arvense L Aerial parts Phenolic compound Oh et al. (2004)
9. Luteolin Equisetum arvense L Aerial parts Flavonoid Domitrovic et al. (2009)
10. Phyllanthin Phyllanthus amarus Schum Leaves, roots,
seed
Flavonoids Pramyothin et al. (2007)
11. Agathisﬂavone Canarium manii King Whole Biﬂavonoid Lin et al. (1997)
12. Wighteone Cudrania cochinchinensis (Lour.) Roots Flavonoid Lin et al. (1996)
13. Naringenin Cudrania cochinchinensis (Lour.) Roots Flavonoid Lee et al. (2004)
14. Kaempferol Rhodiola sachalinensi Roots Phenolic compound Song et al. (2003)
15. Salidroside Rhodiola sachalinensi Roots Phenolic compound Wu et al. (2009)
16. Rutin Artemisia scoparia Stem Flavonoid Janbaz et al. (2002)
17. Troxerutin Artemisia scoparia Leaves Flavonoid Adam et al. (2005)
18. Kolaviron Garcinia kola Seeds Biﬂavonoid Farombi (2000)
19. Catechin Camellia sinensis Whole Flavonoid Hesham and
Beshbishy (2005)
20. Glycyrrihizin Glycyrrhiza glabra Linn Root/stolon Flavonoid Shiota et al. (1999)
21. 3,5-Di-O-caﬀeoyl quinic acid Suaeda glauca Seeds Phenoic compounds An et al. (2008)
22. Curcumin Curcuma longa Rhizomes Curcumin, carotene,
pigment
Somchit et al. (2002)
23. Galangin Alpinia galangal Linn Rhizomes Flavonoid, ﬂavonol Zhang et al. (2010)
24. Scopoletin Solanum lyratum Aerial parts Coumarin Kang et al. (1998)
25. Vitexin 7-O-b-L-glucopyranoside &
vitexin 200-O-b-glucopyranoside
Vitis vinifera Seeds Flavones Kim et al. (2004)
26. Arjunolic acid Terminalia arjuna Bark Triterpenoid saponins Hemlatha et al. (2010)
27. Andrographolide Andrographis paniculata Leaves Diterpenoid lactone Handa and
Sharma (1990)
28. Gossypin Hibiscus vitifolius Whole Glucosyl ﬂavone Ralhan et al. (2009)
29. Plumbagin Plumbago zeylanica Root Pigment Ralhan et al. (2009)
30. Epicatechin Nelumbo nucifera Leaves Flavanols Raj et al. (2010)
31. Isoquercitrin Phyllanthus amarus Schum Whole plant Flavonoid Huang et al. (2010)
32. Wedelolactone Phyllanthus amarus Schum Aerial parts Polyphenolics Dalal et al. (2010)
33. Silybin, isosilybin,
silychristin, silydianin
Silybum marianum Seeds Flavonoids and
phenolic compounds
Thorat et al. (2010)
34. Eclipta alba Green tea (Camellia sinensis) Whole Flavonoid Strobel and Daisy (2003)
35. Halichrysin A and B Helichrysum arenarium (L.) Moench Whole Isoﬂavonoid Thorat et al. (2010)
A quest for staunch effects of ﬂavonoids: Utopian protection S1821care and most drugs come from plants (Rajbhandari, 2009).
The plants may offer new alternatives to the limited therapeu-
tic options that exist at present in the treatment of liver and
other diseases or their symptoms, and they should be consid-
ered for future studies. In view of the need for safe and effec-
tive treatment, a study of the role of silymarin in the
management of non-B acute viral hepatitis was investigated,
which showed signiﬁcantly earlier recovery from hepatomegaly
and enlarged spleen in patients receiving silymarin. Both
meciadiol and sofalcone have been studied for anticancer effec-
tiveness and found to be effective in clinical trials. Sofalcone
has been used clinically in Japan for treatment of gastroduode-
nal ulcers (Narayana et al., 2001). The present study identiﬁed
ﬂavonoids, triterpenes and phenolic compounds as classes ofcompounds with hepatoprotective potential. The potent hepa-
toprotective activities of the chemically deﬁned molecules iso-
lated from natural products represent an exciting advance in
the search for effective liver protective agents, especially
now, when there is an urgent need for new innovative drug
leads. Further studies including clinical trials need to be car-
ried out to ascertain the safety of these compounds as a good
alternative to conventional drugs in the treatment of liver
diseases.
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